OTCPK:ARXX.L

Stock Analysis Report

Executive Summary

AirXpanders, Inc., a medical device company, designs, manufactures, sells, and distributes medical devices in the Australia, the United States, and Europe.

Snowflake

Fundamentals

Limited growth with worrying balance sheet.

Risks

  • AirXpanders is covered by less than 3 analysts.

Similar Companies

Share Price & News

How has AirXpanders's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

0%

OTCPK:ARXX.L

1.5%

US Medical Equipment

0.8%

US Market


1 Year Return

n/a

OTCPK:ARXX.L

9.7%

US Medical Equipment

1.9%

US Market

No trading data on ARXX.L.

No trading data on ARXX.L.


Share holder returns

ARXX.LIndustryMarket
7 Day0%1.5%0.8%
30 Day0%0.7%3.4%
90 Dayn/a2.4%2.1%
1 Yearn/a10.6%9.7%4.2%1.9%
3 Yearn/a70.2%65.0%46.7%37.2%
5 Yearn/a136.0%109.1%62.3%44.5%

Price Volatility Vs. Market

How volatile is AirXpanders's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is AirXpanders undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether AirXpanders is trading at an attractive price based on the cash flow it is expected to produce in the future. But as AirXpanders has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

  • Take a look at our analysis of ARXX.L’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  • When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through AirXpanders regulatory filings here.
  • Explore potentially undervalued companies in the Healthcare industry.

Future Growth

How is AirXpanders expected to perform in the next 1 to 3 years based on estimates from 1 analyst?

43.0%

Forecasted annual revenue growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

AirXpanders's revenue is expected to grow significantly at over 20% yearly.

Unable to determine if AirXpanders is high growth as no earnings estimate data is available.

AirXpanders's revenue growth is expected to exceed the United States of America market average.

Unable to compare AirXpanders's earnings growth to the United States of America market average as no estimate data is available.

Unable to compare AirXpanders's earnings growth to the low risk savings rate as no estimate data is available.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if AirXpanders will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has AirXpanders performed over the past 5 years?

-30.4%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

AirXpanders does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare AirXpanders's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare AirXpanders's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if AirXpanders has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.


Return on Assets

It is difficult to establish if AirXpanders has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if AirXpanders improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.


Next Steps

Financial Health

How is AirXpanders's financial position?


Financial Position Analysis

AirXpanders's short term (1 year) commitments are greater than its holdings of cash and other short term assets.

AirXpanders has no long term commitments.


Debt to Equity History and Analysis

AirXpanders has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.

Irrelevant to check if AirXpanders's debt level has increased considering it has negative shareholder equity.


Balance Sheet

High level of physical assets or inventory.

AirXpanders has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

AirXpanders has less than a year of cash runway based on current free cash flow.

AirXpanders has less than a year of cash runway if free cash flow continues to grow at historical rates of 18.8% each year.


Next Steps

Dividend

What is AirXpanders's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate AirXpanders's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate AirXpanders's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as AirXpanders has not reported any payouts.

Unable to verify if AirXpanders's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as AirXpanders has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of AirXpanders's salary, the management and board of directors tenure and is there insider trading?

2.7yrs

Average board tenure


CEO

Frank Grillo (57yo)

1.1yrs

Tenure

US$1,393,015

Compensation

Mr. Frank P. Grillo, also known as Frank, has been the President, Chief Executive Officer and Executive Director of AirXpanders, Inc. since joining in June 12, 2018 and also serves as its Principal Financi ...


CEO Compensation Analysis

Frank's remuneration is higher than average for companies of similar size in United States of America.

Insufficient data for Frank to compare compensation growth.


Board Age and Tenure

2.7yrs

Average Tenure

65yo

Average Age

The average tenure for the AirXpanders board of directors is less than 3 years, this suggests a new board.


Insider Trading

No 3 month individual insider trading information.


Recent Insider Transactions

BuyUS$50,24230 Oct 18
Barry Cheskin
EntityIndividual
Role
Chairman of the Board
Co-Founder & Non-Executive Chairman of the Board
Shares897,180
Max PriceUS$0.056

Ownership Breakdown


Management Team

  • Barry Cheskin (58yo)

    Co-Founder & Non-Executive Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$111.32k
  • Frank Grillo (57yo)

    President

    • Tenure: 1.1yrs
    • Compensation: US$1.39m
  • Daniel Jacobs

    Co-Founder & Medical Adviser

    • Tenure: 0yrs
  • Melissa Comunale

    Vice President of Sales

    • Tenure: 1.5yrs

Board Members

  • Dennis Condon (70yo)

    Non-Executive Director

    • Tenure: 6.9yrs
    • Compensation: US$34.74k
  • Barry Cheskin (58yo)

    Co-Founder & Non-Executive Chairman of the Board

    • Tenure: 0yrs
    • Compensation: US$111.32k
  • Greg Lichtwardt (65yo)

    Non-Executive Director

    • Tenure: 3.3yrs
    • Compensation: US$44.89k
  • Frank Grillo (57yo)

    President

    • Tenure: 1.1yrs
    • Compensation: US$1.39m
  • Liz Hammack (67yo)

    Non-Executive Director

    • Tenure: 2.2yrs
    • Compensation: US$34.74k

Company Information

AirXpanders, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: AirXpanders, Inc.
  • Ticker: ARXX.L
  • Exchange: OTCPK
  • Founded: 2005
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$19.546m
  • Listing Market Cap: AU$13.639m
  • Shares outstanding: 558.47m
  • Website: https://www.airxpanders.com

Number of Employees


Location

  • AirXpanders, Inc.
  • 3047 Orchard Parkway
  • San Jose
  • California
  • 95134
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AXPASX (Australian Securities Exchange)YesNPV CDI 1:3AUAUDJun 2015
ARXX.LOTCPK (Pink Sheets LLC)YesNPV CDI 1:3USUSDJun 2015
A1WDB (Deutsche Boerse AG)YesNPV CDI 1:3DEEURJun 2015

Biography

AirXpanders, Inc., a medical device company, designs, manufactures, sells, and distributes medical devices in the Australia, the United States, and Europe. The company's product, AeroForm Tissue Expander S ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/07/25 01:07
End of Day Share Price2019/05/08 00:00
Earnings2019/03/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.